The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3
Open accessAbstract
Recent clinical trials using rapalogues in tuberous sclerosis complex show regression in volume of typically vascularised tumours including angiomyolipomas and subependymal giant cell astrocytomas. By blocking mechanistic/mammalian target of rapamycin complex 1 (mTORC1) signalling, rapalogue efficacy is likely to occur, in part, through suppression of hypoxia-inducible factors (HIFs) and vascular endothelial growth factors (VEGFs). We show that rapamycin reduces HIF-1α protein levels, and to a lesser extent VEGF-A levels, in renal cystadenoma cells in a Tsc2+/− mouse model. We established that mTORC1 drives HIF-1α protein accumulation through enhanced transcription of HIF-1α mRNA, a process that is blocked by either inhibition or knockdown of signal transducer and activation of transcription 3 (STAT3). Furthermore, we demonstrated that STAT3 is directly phosphorylated by mTORC1 on Ser727 during hypoxia, promoting HIF-1α mRNA transcription. mTORC1 also regulates HIF-1α synthesis on a translational level via co-operative regulation of both initiation factor 4E-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase-1 (S6K1), whereas HIF-1α degradation remains unaffected. We therefore proposed that mTORC1 drives HIF-1α synthesis in a multifaceted manner through 4E-BP1/eIF4E, S6K1 and STAT3. Interestingly, we observed a disconnect between HIF-1α protein levels and VEGF-A expression. Although both S6K1 and 4E-BP1 regulate HIF-1α translation, VEGF-A is primarily under the control of 4E-BP1/eIF4E. S6K1 inhibition reduces HIF-1α but not VEGF-A expression, suggesting that mTORC1 mediates VEGF-A expression via both HIF-1α-dependent and -independent mechanisms. Our work has important implications for the treatment of vascularised tumours, where mTORC1 acts as a central mediator of STAT3, HIF-1α, VEGF-A and angiogenesis via multiple signalling mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Activation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020
Wen, Z., Zhong, Z., & Darnell, J. E. (1995) · Cell · doi:10.1016/0092-8674(95)90311-9 · Cited by 1,974
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
A unifying model for mTORC1-mediated regulation of mRNA translation
Thoreen, C. C., Chantranupong, L., Keys, H. R., Wang, T., Gray, N. S., & Sabatini, D. M. (2012) · Nature · doi:10.1038/nature11083 · Cited by 1,477
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
HIF-1 and mechanisms of hypoxia sensing
Semenza, G. L. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00194-0 · Cited by 1,268
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
Regulation of cap-dependent translation by eIF4E inhibitory proteins
Richter, J. D., & Sonenberg, N. (2005) · Nature · doi:10.1038/nature03205 · Cited by 970
Isaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.017 · Cited by 958
Lu, H., Forbes, R. A., & Verma, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202487200 · Cited by 837
Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 810
The TSC-mTOR Signaling Pathway Regulates the Innate Inflammatory Response
Weichhart, T., Costantino, G., Poglitsch, M., Rosner, M., Zeyda, M., Stuhlmeier, K. M., Kolbe, T., Stulnig, T. M., Hörl, W. H., Hengstschläger, M., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.012 · Cited by 801
Regulation of elongation factor 2 kinase by p90RSK1 and p70 S6 kinase
Wang, X. (2001) · The EMBO Journal · doi:10.1093/emboj/20.16.4370 · Cited by 796
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Hypoxia and hypoxia-inducible factors: master regulators of metastasis
Lu, X., & Kang, Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1360 · Cited by 723
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204733200 · Cited by 663
TBC1D7 Is a Third Subunit of the TSC1-TSC2 Complex Upstream of mTORC1
Dibble, C. C., Elis, W., Menon, S., Qin, W., Klekota, J., Asara, J. M., Finan, P. M., Kwiatkowski, D. J., Murphy, L. O., & Manning, B. D. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.009 · Cited by 612
mTOR, translation initiation and cancer
Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209888 · Cited by 607
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604
Treins, C., Giorgetti-Peraldi, S., Murdaca, J., Semenza, G. L., & Van Obberghen, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204152200 · Cited by 539
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
Brugarolas, J. B., Vazquez, F., Reddy, A., Sellers, W. R., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00187-9 · Cited by 528
Land, S. C., & Tee, A. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611782200 · Cited by 507
Self-citationIdentification of a Conserved Motif Required for mTOR Signaling
Schalm, S. S., & Blenis, J. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00762-5 · Cited by 482
Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases
Raught, B., Peiretti, F., Gingras, A., Livingstone, M., Shahbazian, D., Mayeur, G. L., Polakiewicz, R. D., Sonenberg, N., & Hershey, J. W. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600193 · Cited by 473
Yokogami, K., Wakisaka, S., Avruch, J., & Reeves, S. A. (2000) · Current Biology · doi:10.1016/s0960-9822(99)00268-7 · Cited by 469
Dazert, E., & Hall, M. N. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.003 · Cited by 460
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
García-Martínez, J. M., Moran, J., Clarke, R. G., Gray, A., Cosulich, S. C., Chresta, C. M., & Alessi, D. R. (2009) · Biochemical Journal · doi:10.1042/bj20090489 · Cited by 455
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Phung, T. L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., Perruzzi, C., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 438
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation
Wong, C. C.-L., Gilkes, D. M., Zhang, H., Chen, J., Wei, H., Chaturvedi, P., Fraley, S. I., Wong, C.-M., Khoo, U.-S., Ng, I. O.-L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113483108 · Cited by 437
mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin
Kang, S. A., Pacold, M. E., Cervantes, C. L., Lim, D., Lou, H. J., Ottina, K., Gray, N. S., Turk, B. E., Yaffe, M. B., & Sabatini, D. M. (2013) · Science · doi:10.1126/science.1236566 · Cited by 431
HIF-1 regulation: not so easy come, easy go
Koh, M. Y., Spivak-Kroizman, T. R., & Powis, G. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.08.002 · Cited by 339
Leucine and mTORC1: a complex relationship
Dodd, K. M., & Tee, A. R. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00525.2011 · Cited by 293
Self-citationPore, N., Jiang, Z., Gupta, A., Cerniglia, G., Kao, G. D., & Maity, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3090 · Cited by 268
Pearce, L. R., Alton, G. R., Richter, D. T., Kath, J. C., Lingardo, L., Chapman, J., Hwang, C., & Alessi, D. R. (2010) · Biochemical Journal · doi:10.1042/bj20101024 · Cited by 265
HIF-1α controls extracellular matrix synthesis by epiphyseal chondrocytes
Pfander, D., Cramer, T., Schipani, E., & Johnson, R. S. (2003) · Journal of Cell Science · doi:10.1242/jcs.00385 · Cited by 258
The Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer Microenvironment
Li, N., Grivennikov, S. I., & Karin, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.018 · Cited by 245
Lin, L., Hutzen, B., Zuo, M., Ball, S., Deangelis, S., Foust, E., Pandit, B., Ihnat, M. A., Shenoy, S. S., Kulp, S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2468 · Cited by 234
Sirolimus Therapy in Tuberous Sclerosis or Sporadic Lymphangioleiomyomatosis
Davies, D. M., Johnson, S. R., Tattersfield, A. E., Kingswood, J. C., Cox, J. A., McCartney, D. L., Doyle, T., Elmslie, F., Saggar, A., de Vries, P. J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmc072500 · Cited by 211
Self-citationNiu, G., Briggs, J., Deng, J., Ma, Y., Lee, H., Kortylewski, M., Kujawski, M., Kay, H., Cress, W. D., Jove, R., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2177 · Cited by 177
Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes
Brugarolas, J., & Kaelin, W. G. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.020 · Cited by 160
Barbieri, I., Pensa, S., Pannellini, T., Quaglino, E., Maritano, D., Demaria, M., Voster, A., Turkson, J., Cavallo, F., Watson, C. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2840 · Cited by 148
Urano, J., Sato, T., Matsuo, T., Otsubo, Y., Yamamoto, M. P., & Tamanoi, F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608510104 · Cited by 145
The Diverse Clinical Manifestations of Tuberous Sclerosis Complex: A Review
Rosser, T. L., Panigrahy, A., & McClintock, W. (2006) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2006.01.008 · Cited by 121
Minet, E., Ernest, I., Michel, G., Roland, I., Remacle, J., Raes, M. J., & Michiels, C. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0995 · Cited by 118
Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms
Arbiser, J. L., Brat, D. J., Hunter, S., D'Armiento, J. M., Henske, E. P., Arbiser, Z. K., Bai, X., Goldberg, G. N., Cohen, C., & Weiss, S. W. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120530 · Cited by 85
Dunlop, E. A., Dodd, K. M., Seymour, L. A., & Tee, A. R. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.02.024 · Cited by 82
Self-citationTandon, P., Gallo, C. A., Khatri, S., Barger, J. F., Yepiskoposyan, H., & Plas, D. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013629108 · Cited by 77
Preston, R. S., Philp, A., Claessens, T., Gijezen, L., Dydensborg, A. B., Dunlop, E. A., Harper, K., Brinkhuizen, T., Menko, F. H., Davies, D. M., et al. (2010) · Oncogene · doi:10.1038/onc.2010.497 · Cited by 72
Self-citationTORgeting oncogene addiction for cancer therapy
Choo, A. Y., & Blenis, J. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.021 · Cited by 62
Schalm, S. S., Tee, A. R., & Blenis, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413995200 · Cited by 55
Self-citationEl-Hashemite, N., Zhang, H., Walker, V., Hoffmeister, K. M., & Kwiatkowski, D. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3609 · Cited by 54
Woodrum, C., Nobil, A. M., & Dabora, S. L. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-14 · Cited by 46
Guo, Y., & Kwiatkowski, D. J. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0605 · Cited by 45
Interferon-γ-Jak-Stat Signaling in Pulmonary Lymphangioleiomyomatosis and Renal Angiomyolipoma
El-Hashemite, N., & Kwiatkowski, D. J. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2005-0152rc · Cited by 33
Characterizing the interaction of the mammalian eIF4E‐related protein 4EHP with 4E‐BP1
Tee, A. R., Tee, J. A., & Blenis, J. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00313-8 · Cited by 26
Self-citationYang, J., Kalogerou, M., Samsel, P. A., Zhang, Y., Griffiths, D. F. R., Gallacher, J., Sampson, J. R., & Shen, M. H. (2014) · Oncogene · doi:10.1038/onc.2014.17 · Cited by 16
Self-citationDunlop, E. A., Dodd, K. M., Land, S. C., Davies, P. A., Martins, N., Stuart, H., McKee, S. A., Kingswood, J. C., Saggar, A., Corderio, I., et al. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.38 · Cited by 11
Self-citationmTORC1-Mediated Control of Protein Translation
Dempsey, J. M., Mahoney, S. J., & Blenis, J. (2010) · The Enzymes · doi:10.1016/s1874-6047(10)28001-0 · Cited by 8
Cited by
Regulation and metabolic functions of mTORC1 and mTORC2
Szwed, A., Kim, E., & Jacinto, E. (2021) · Physiological Reviews · doi:10.1152/physrev.00026.2020 · Cited by 813
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.013 · Cited by 626
“(E) Diagram of interactions involving PI3K/AKT/MTOR pathway represented by selected features from (C) and (D) (Carbonneau et al., 2016; Dodd et al., 2015; Guo et al., 2016; Weiler et al., 2014), with differential protein expression patterns represented, comparing tumors in HIGH P-AKT group with…”
MethodmTOR coordinates protein synthesis, mitochondrial activity and proliferation
Morita, M., Gravel, S.-P., Hulea, L., Larsson, O., Pollak, M., St-Pierre, J., & Topisirovic, I. (2015) · Cell Cycle · doi:10.4161/15384101.2014.991572 · Cited by 552
Hypoxia signaling in human health and diseases: implications and prospects for therapeutics
Luo, Z., Tian, M., Yang, G., Tan, Q., Chen, Y., Li, G., Zhang, Q., Li, Y., Wan, P., & Wu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01080-1 · Cited by 499
mTOR substrate phosphorylation in growth control
Battaglioni, S., Benjamin, D., Wälchli, M., Maier, T., & Hall, M. N. (2022) · Cell · doi:10.1016/j.cell.2022.04.013 · Cited by 434
Metadata
- Authors
- Dodd, K. M., Yang, J., Shen, M. H., Sampson, J. R., & Tee, A. R.
- Venue
- Oncogene
- Published
- 2014-06-16
- Volume
- 34
- Issue
- 17
- Pages
- 2239-2250
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2001775267
- Cited by
- 391
- References
- 69
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.